Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Ronald Levy

Gastroenterology Lake Worth, FL Medical Doctor

NPI 1558350975 CMS profile 251880

6944 Lake Worth Rd, 2Nd Floor, Lake Worth, FL 33467

Open in the dashboard

General payments

$8,000

407 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Ronald Levy of Lake Worth, FL is reported in the CMS Open Payments database as having received $8,000 across 407 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 77th percentile of Gastroenterology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,331 102
2024 General $1,345 64
2023 General $920 42
2022 General $1,028 53
2021 General $935 50
2020 General $447 24
2019 General $994 72

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Ronald Levy
  • Gastroenterology median
  • Middle half of Gastroenterology
  • National median

In program year 2025, general payments to Ronald Levy were reported at $2,331. Among 13,050 Gastroenterology profiles paid that year, the median was $639 and the middle half received between $167 and $1,700.

Show as a table
Year Ronald Levy Gastroenterology median Middle half National median
2019 $994 $417 $126–$1,100 $163
2020 $447 $224 $74–$624 $114
2021 $935 $352 $106–$1,054 $132
2022 $1,028 $448 $129–$1,270 $149
2023 $920 $533 $150–$1,390 $160
2024 $1,345 $605 $160–$1,606 $164
2025 $2,331 $639 $167–$1,700 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $1,856 112 payments
  2. Janssen Biotech, Inc. $1,123 41 payments
  3. Salix Pharmaceuticals, a division of Bausch Health US, LLC $670 47 payments
  4. Celgene Corporation $431 32 payments
  5. Lilly USA, LLC $394 16 payments
  6. Madrigal Pharmaceuticals $320 8 payments
  7. Merck Sharp & Dohme Corporation $288 13 payments
  8. E.R. Squibb & Sons, L.L.C. $246 3 payments
  9. Takeda Pharmaceuticals U.S.A., Inc. $232 11 payments
  10. Braintree Laboratories, Inc. $216 21 payments
  11. Other $2,223 103 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $7,508 383 payments
  2. Education $492 24 payments
Products named General payments · program years 2019–2025
  1. RINVOQ $689 43 payments
  2. XIFAXAN $689 48 payments
  3. ZEPOSIA $678 35 payments
  4. TREMFYA $633 23 payments
  5. SKYRIZI $497 32 payments
  6. STELARA $490 18 payments
  7. HUMIRA $412 23 payments
  8. OMVOH $369 15 payments
  9. MAVYRET $290 18 payments
  10. DIFICID $288 13 payments
  11. Other $3,713 198 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 27 drugs

Part D claims

2,080

Median for Gastroenterology: 569

Drug cost

$253,419

Median for Gastroenterology: $104,976

Branded share of claims

10.9%

Median for Gastroenterology: 31.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Humira Adalimumab Brand 12 $80,769
Xifaxan Rifaximin Brand 22 $68,179
Linzess Linaclotide Brand 35 $27,520
Viberzi Eluxadoline Brand 12 $17,013
Mesalamine Generic 33 $13,619
Pantoprazole Sodium Generic 850 $8,941
Clenpiq Sod Picosulf/Mag Ox/Citric Ac Brand 44 $7,501
Dexlansoprazole Dr Dexlansoprazole Brand 15 $5,882
Plenvu Peg3350/Sod Sul/Nacl/Kcl/Asb/C Brand 33 $4,828
Ursodiol Generic 22 $3,846

The 10 drugs with the highest cost, of 27 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 14,294 Part D prescribers listed as Gastroenterology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 43 billing codes

Paid by Medicare

$680,382

Of which drugs: $554,777

Medicare patients

627

Average age 75

Services billed

33,994

353 women, 274 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 54%
Ischemic heart disease 44%
Diabetes 36%
Chronic kidney disease 28%
Depression 28%
Osteoporosis 23%
Cancer 22%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, vedolizumab, 1 mg J3380 Office 41 25,500 $443,585
Injection, infliximab, excludes biosimilar, 10 mg J1745 Office 18 2,210 $54,993

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 24 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
OMVOH
  • Lilly USA, LLC $192
$192 — —
ZEPOSIA
  • Celgene Corporation $131
$131 — —
STELARA
  • Janssen Biotech, Inc. $120
$120 — —
RINVOQ
  • AbbVie, Inc. $84
$84 — —
IBSRELA
  • Ardelyx, Inc. $79
$79 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 24 in the dashboard with a free account

Records

407 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Gastroenterology in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record